A healthy decision in Generic Pharmaceuticals
Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a portfolio of approximately 1000 compounds and sells its products in more than 130 countries.
Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these medicines along with pharmaceutical and biotechnological active substances and anti-infectives.
In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE (Austria). In 2009, Sandoz employed around 23,000 people worldwide and posted sales of USD 7.5 billion. Sandoz global headquarters are based in Holzkirchen, Germany, located just south of Munich.
Generic pharmaceuticals are the bioequivalent of an innovative, brand name product. This includes dosage form, safety, strength, route of administration, quality, performance characteristics and intended use. Generics are held to the same strict standards as the innovator product, dictated by the FDA and other regulatory agencies throughout the world. Although generic pharmaceuticals are chemically identical to their branded counterparts, they traditionally cost consumers less than the brand product.
The finished dosage forms are sold to wholesalers, pharmacies, hospitals and other healthcare outlets. Our Anti-Infectives unit manufactures active pharmaceutical ingredients and their intermediates for internal requirements and industrial partners.
Sandoz nu are in prezent job-uri active.
Iata cele mai noi job-uri de pe Hipo:
